119 related articles for article (PubMed ID: 35916335)
1. Antitumour effects of a solid lipid nanoparticle loaded with gemcitabine and oxaliplatin on the viability, apoptosis, autophagy, and Hsp90 of ovarian cancer cells.
Al-Mutairi AA; Alkhatib MH
J Microencapsul; 2022 Aug; 39(5):467-480. PubMed ID: 35916335
[TBL] [Abstract][Full Text] [Related]
2. Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Tian Y; Han W; Fu L; Lv K; Zhou X
Environ Toxicol; 2023 Aug; 38(8):1835-1845. PubMed ID: 37186415
[TBL] [Abstract][Full Text] [Related]
3. Thermosensitive liposomes for the delivery of gemcitabine and oxaliplatin to tumors.
May JP; Ernsting MJ; Undzys E; Li SD
Mol Pharm; 2013 Dec; 10(12):4499-508. PubMed ID: 24152292
[TBL] [Abstract][Full Text] [Related]
4. Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment.
Yuan YG; Peng QL; Gurunathan S
Int J Nanomedicine; 2017; 12():6487-6502. PubMed ID: 28919750
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Tang Z; Feng W; Yang Y; Wang Q
Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830
[TBL] [Abstract][Full Text] [Related]
6. Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy.
Behl A; Sarwalia P; Kumar S; Behera C; Mintoo MJ; Datta TK; Gupta PN; Chhillar AK
Mol Pharm; 2022 Jul; 19(7):2429-2440. PubMed ID: 35639628
[TBL] [Abstract][Full Text] [Related]
7. Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
Huang XL; Zhang H; Yang XY; Dong XY; Xie XY; Yin HB; Gou X; Lin Y; He WY
Anticancer Drugs; 2017 Jul; 28(6):596-602. PubMed ID: 28430744
[TBL] [Abstract][Full Text] [Related]
8. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells.
Jing W; Song N; Liu Y; Qu X; Hou K; Yang X; Che X
Mol Med Rep; 2018 Jan; 17(1):117-124. PubMed ID: 29115606
[TBL] [Abstract][Full Text] [Related]
9. Polymer Coated Iron Nanoparticles: Radiolabeling & In vitro Studies.
Yilmaz S; Ichedef C; Karatay KB; Teksöz S
Curr Radiopharm; 2021; 14(1):37-45. PubMed ID: 32351192
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
Airoldi M; Cattel L; Passera R; Pedani F; Milla P; Zanon C
Pancreas; 2006 Jan; 32(1):44-50. PubMed ID: 16340743
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.
Devulapally R; Foygel K; Sekar TV; Willmann JK; Paulmurugan R
ACS Appl Mater Interfaces; 2016 Dec; 8(49):33412-33422. PubMed ID: 27960411
[TBL] [Abstract][Full Text] [Related]
12. Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats.
Karuppaiah A; Babu D; Selvaraj D; Natrajan T; Rajan R; Gautam M; Ranganathan H; Siram K; Nesamony J; Sankar V
Eur J Pharm Sci; 2021 Oct; 165():105938. PubMed ID: 34256103
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
Airoldi M; Cattel L; Passera R; Pedani F; Delprino L; Micari C
Am J Clin Oncol; 2006 Oct; 29(5):490-4. PubMed ID: 17023785
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells.
Affram KO; Smith T; Ofori E; Krishnan S; Underwood P; Trevino JG; Agyare E
J Drug Deliv Sci Technol; 2020 Feb; 55():. PubMed ID: 31903101
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN
Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611
[TBL] [Abstract][Full Text] [Related]
16. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor efficacy of folate modified PLGA-based nanoparticles for the co-delivery of drugs in ovarian cancer.
Li S; Li X; Ding J; Han L; Guo X
Drug Des Devel Ther; 2019; 13():1271-1280. PubMed ID: 31114163
[No Abstract] [Full Text] [Related]
18. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy.
Zhao X; Yang K; Zhao R; Ji T; Wang X; Yang X; Zhang Y; Cheng K; Liu S; Hao J; Ren H; Leong KW; Nie G
Biomaterials; 2016 Sep; 102():187-97. PubMed ID: 27343466
[TBL] [Abstract][Full Text] [Related]
19. Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer.
Du W; Yang X; He S; Wang J; Guo Y; Kou B; Jiang Y; Bian P; Li B; Yin L
Drug Deliv; 2021 Dec; 28(1):920-929. PubMed ID: 33974471
[TBL] [Abstract][Full Text] [Related]
20. Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows
Liu D; Zhang W; Liu X; Qiu R
Drug Deliv; 2021 Dec; 28(1):776-786. PubMed ID: 33866910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
